Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 2201.

https://doi.org/10.1182/blood.V114.22.2201.2201

Published: 2009

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

Blood (2008) 112 (11): 2103.

https://doi.org/10.1182/blood.V112.11.2103.2103

Published: 2008

Journal Articles

Fludarabine, Mitoxantrone and Dexametasone in the Treatment of Relapsed and Refractory Low-Grade Non-Hodgkin Lymphoma.

Joanna Sawczuk-Chabin, MD, Ewa Kalinka, MD, PhD, Piotr Centkowski, MD, Katarzyna Budziszewska, MD, PhD, Bernadeta Ceglarek, MD, PhD, Jacek Najda, MD, PhD, Maria Blasinska-Morawiec, MD, PhD, Kazimierz Sulek, MD, PhD, Jerzy Holowiecki, MD, PhD, Lech Konopka, MD, PhD, Krzysztof Warzocha, MD, PhD, for Polish Lymphoma Research Group

Blood (2005) 106 (11): 4738.

https://doi.org/10.1182/blood.V106.11.4738.4738

Published: 2005

Journal Articles

Randomized Comparison of Cladribine with Cyclophosphamide and Fludarabine with Cyclophosphamide in Previously Untreated Progressive and Symptomatic Chronic Lymphocytic Leukemia: The Interim Analysis of PALG CLL3 Trial.

Blood (2005) 106 (11): 2121.

https://doi.org/10.1182/blood.V106.11.2121.2121

Published: 2005

Journal Articles

Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.

Tadeusz Robak, MD, PhD, Jerzy Z. Blonski, Joanna Gora-Tybor, Marek Kasznicki, Jadwiga Dwilewicz-Trojaczek, Agnieszka Tomaszewska, Lech Konopka, Bernadeta Ceglarek, Janusz Kloczko, Jaroslaw Sokolowski, Anna Dmoszynska, Malgorzata Kowal, Krystyna Zawilska, Beata Stella-Holowiecka, Kazimierz Sulek, Kazimierz Kuliczkowski, Krzysztof Warzocha, Malgorzata Calbecka, Aleksander Skotnicki

Blood (2004) 104 (11): 337.

https://doi.org/10.1182/blood.V104.11.337.337

Published: 2004

Journal Articles

Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis.

Blood (2004) 104 (11): 3305.

https://doi.org/10.1182/blood.V104.11.3305.3305

Published: 2004

Journal Articles

The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.

Tadeusz Robak, Jerzy Z. Blonski, Marek Kasznicki, Joanna Gora-Tybor, Anna Dmoszynska, Maria Wojtaszko, Aleksander Skotnicki, Wieslaw Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadeta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sulek, Krzysztof Warzocha

Blood (2004) 104 (11): 4819.

https://doi.org/10.1182/blood.V104.11.4819.4819

Published: 2004

Journal Articles

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial

Tadeusz Robak, Jerzy Z. Bloński, Marek Kasznicki, Maria Blasińska-Morawiec, Euzebiusz Krykowski, Anna Dmoszyńska, Halina Mrugala-Śpiewak, Aleksander B. Skotnicki, Wieslaw Nowak, Lech Konopka, Bernadeta Ceglarek, Stanislaw Maj, Jadwiga Dwilewicz-Trojaczek, Andrzej Hellmann, Ignacy Urasiński, Barbara Zdziarska, Sabina Kotlarek-Haus, Stanislaw Potoczek, Pawel Grieb

Blood (2000) 96 (8): 2723–2729.

https://doi.org/10.1182/blood.V96.8.2723

Published: 2000

NARROW

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

Fludarabine, Mitoxantrone and Dexametasone in the Treatment of Relapsed and Refractory Low-Grade Non-Hodgkin Lymphoma.

Randomized Comparison of Cladribine with Cyclophosphamide and Fludarabine with Cyclophosphamide in Previously Untreated Progressive and Symptomatic Chronic Lymphocytic Leukemia: The Interim Analysis of PALG CLL3 Trial.

Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.

Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis.

The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only